Eluvia Randomised Controlled Trials
Discover the evidence-backed solution for Superficial Femoral Artery (SFA) disease with Eluvia Drug-Eluting Stent.
Backed by three Randomised Controlled Trials, Boston Scientific confirms Eluvia's superiority, safety, and efficacy.
The results demonstrate that in any lesion, in any patient, and any trial, we show consistent results of ~90% primary patency at 1 year.
SPORTS is Investigator-Sponsored, Core-lab Adjudicated, Randomised Controlled Trial Evaluating Drug-Eluting Stent or Primary Bare Nitinol Stent Application Versus Drug-Coated Balloons in Long SFA Lesions.
EMINENT is the largest Randomised Controlled Trial (2:1) comparing Eluvia™ Drug-Eluting Vascular Stent System to self-expanding bare metal stents (BMS) for SFA/PPA; EU multi-center; superiority trial; core lab adjudicated.
IMPERIAL is the world’s first head-to-head DES SFA Trial, evaluating Boston Scientific Corporation’s Eluvia™ Drug-Eluting Vascular Stent System and Cook Medical’s Zilver™ PTX™ Stent.
